KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) FCF Margin (2019 - 2025)

Historic FCF Margin for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to 15.03%.

  • Royalty Pharma's FCF Margin fell 264300.0% to 15.03% in Q4 2025 from the same period last year, while for Dec 2025 it was 33.31%, marking a year-over-year increase of 216800.0%. This contributed to the annual value of 33.31% for FY2025, which is 216800.0% up from last year.
  • Per Royalty Pharma's latest filing, its FCF Margin stood at 15.03% for Q4 2025, which was down 264300.0% from 42.55% recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's FCF Margin ranged from a high of 104.71% in Q1 2025 and a low of 147.88% during Q3 2021
  • Moreover, its 5-year median value for FCF Margin was 48.37% (2021), whereas its average is 19.22%.
  • As far as peak fluctuations go, Royalty Pharma's FCF Margin soared by 1584000bps in 2023, and later tumbled by -1148100bps in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's FCF Margin stood at 55.28% in 2021, then increased by 2bps to 56.51% in 2022, then tumbled by -168bps to 38.52% in 2023, then skyrocketed by 208bps to 41.46% in 2024, then tumbled by -64bps to 15.03% in 2025.
  • Its FCF Margin stands at 15.03% for Q4 2025, versus 42.55% for Q3 2025 and 62.71% for Q2 2025.